Distinct clinical outcomes for cytogenetic abnormalities evolving from aplastic anemia

Area of Science:

• Hematology
• Cytogenetics
• Oncology

Background:

• Aplastic anemia (AA) is a serious condition with a risk of evolving into clonal hematologic diseases like myelodysplasia (MDS) and leukemia.
• This evolution is typically marked by the emergence of cytogenetic abnormalities in bone marrow cells.

Purpose of the Study:

• To analyze clonal karyotypic evolution in a cohort of patients with aplastic anemia.
• To identify common cytogenetic abnormalities and their correlation with clinical outcomes and disease progression.

Main Methods:

• Analysis of bone marrow karyotypes in 30 patients with aplastic anemia undergoing frequent examinations.
• Correlation of observed cytogenetic patterns with clinical course, treatment response, and survival.

Main Results:

• Clonal karyotypic evolution occurred at a constant rate, with 50% of cases developing abnormalities within 30 months.
• Abnormalities of chromosome 7 (40% of cases) and complex cytogenetic alterations were associated with increased risk of leukemic transformation and mortality.
• Trisomy 8, often seen in patients responding to immunosuppression (cyclosporine A), indicated a favorable prognosis, contrasting with its outcome in primary MDS.

Conclusions:

• Cytogenetic analysis is crucial for monitoring aplastic anemia patients for clonal evolution.
• Specific chromosomal abnormalities, particularly chromosome 7 defects, predict a poor prognosis and leukemic transformation, while trisomy 8 suggests a better outcome in AA.
• The prognosis associated with trisomy 8 in aplastic anemia is more favorable than in myelodysplastic syndromes.